The development comes after the subject expert committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) recommended Oxford-AstraZeneca’s vaccine for emergency use and Covaxin for restricted use.
Posted from: this blog via Microsoft Flow.
No comments:
Post a Comment